当前位置：
X-MOL 学术
›
Expert Opin. Investig. Drugs
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study
Expert Opinion on Investigational Drugs ( IF 4.9 ) Pub Date : 2024-02-12 , DOI: 10.1080/13543784.2024.2305134 Yicong Bian 1, 2 , Sheng Ma 1, 2 , Qingqing Yao 1 , Tao Hu 1 , Mingjing Ge 3 , Hongting Li 3 , Shansong Zheng 3 , Zheming Gu 4 , Hao Feng 4 , Zhenwen Yu 4 , Chenrong Huang 1 , Hua Zhang 1 , Limei Zhao 2 , Liyan Miao 1
Expert Opinion on Investigational Drugs ( IF 4.9 ) Pub Date : 2024-02-12 , DOI: 10.1080/13543784.2024.2305134 Yicong Bian 1, 2 , Sheng Ma 1, 2 , Qingqing Yao 1 , Tao Hu 1 , Mingjing Ge 3 , Hongting Li 3 , Shansong Zheng 3 , Zheming Gu 4 , Hao Feng 4 , Zhenwen Yu 4 , Chenrong Huang 1 , Hua Zhang 1 , Limei Zhao 2 , Liyan Miao 1
Affiliation
Iruplinalkib is a novel anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive crizotinib-resistant NSCLC.A single oral dose of 120 mg/3.7 MBq [14C]iruplinalkib was administer...
中文翻译：
新型 ALK 抑制剂 iruplinalkib (WX-0593) 在健康受试者中的药代动力学、代谢、排泄和安全性：I 期人体放射性标记质量平衡研究
Iruplinalkib 是一种新型间变性淋巴瘤激酶 (ALK) 抑制剂，用于治疗 ALK 阳性克唑替尼耐药 NSCLC。单次口服剂量 120 mg/3.7 MBq [14C]iruplinalkib...
更新日期：2024-02-13
中文翻译：
新型 ALK 抑制剂 iruplinalkib (WX-0593) 在健康受试者中的药代动力学、代谢、排泄和安全性：I 期人体放射性标记质量平衡研究
Iruplinalkib 是一种新型间变性淋巴瘤激酶 (ALK) 抑制剂，用于治疗 ALK 阳性克唑替尼耐药 NSCLC。单次口服剂量 120 mg/3.7 MBq [14C]iruplinalkib...
京公网安备 11010802027423号